TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04915742

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercises
Description: The exercise group ha in FTAs 2, each session will be 30 minutes of evil sown in stretching , which made combining relaxation and strengthening exercises therapeutic exercise program for 6 weeks from the online platform will be implemented in the form of group exercise form is planned.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: thetahealing and exercises
Description: The exercise group ha in FTAs 2, each session will be 30 minutes of evil sown in stretching , which made combining relaxation and strengthening exercises therapeutic exercise program for 6 weeks from the online platform will be implemented in the form of group exercise form is planned.~The exercise and Thetahealing treatment group, on the other hand, is planned for 6 weeks , 1 session per week, 30 minutes per session, in addition to the exercise sessions, the first and last sessions to be individual and personalized .~Applications will be carried out on the online platform.
Study: NCT04720742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analytical Treatment Interruption + bNAbs infusion
Description: The participant will perform an Analytical Treatment Interruption (ATI) of up to 18 months of duration. During the first 8 months, the participants will be infused once per month with a combination of the broadly neutralizing antibodies (bNAbs) 3BNC117 and 10-1074
Study: NCT04493658

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaires
Description: Cognitive ability questionnaires, dry eye symptom questionnaires (Ocular Surface Disease Index, Impact of Dry Eye in Everyday Life, Visual Function Questionnaire-25, Eye Dryness Visual Analog Scale, Visual Fatigue Visual Analog Scale, Visual Tasking Questionnaire, Short Form Survey-36, Profile of Fatigue and Discomfort, European League Against Rheumatism Sjögren's Syndrome Patient Reported Index) will be completed by the subjects

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaires
Description: Cognitive ability questionnaires, dry eye symptom questionnaires (Ocular Surface Disease Index, Impact of Dry Eye in Everyday Life, Visual Function Questionnaire-25, Eye Dryness Visual Analog Scale, Visual Fatigue Visual Analog Scale, Visual Tasking Questionnaire, Short Form Survey-36, Profile of Fatigue and Discomfort, European League Against Rheumatism Sjögren's Syndrome Patient Reported Index) will be completed by the subjects

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaires
Description: Cognitive ability questionnaires, dry eye symptom questionnaires (Ocular Surface Disease Index, Impact of Dry Eye in Everyday Life, Visual Function Questionnaire-25, Eye Dryness Visual Analog Scale, Visual Fatigue Visual Analog Scale, Visual Tasking Questionnaire, Short Form Survey-36, Profile of Fatigue and Discomfort, European League Against Rheumatism Sjögren's Syndrome Patient Reported Index) will be completed by the subjects

Intervention type: DIAGNOSTIC_TEST
Intervention: Tear fluid sampling
Description: Using microcapillary tubes, 1 microliter of tear fluid will be collected in both eyes of each subject.

Intervention type: DIAGNOSTIC_TEST
Intervention: Tear fluid sampling
Description: Using microcapillary tubes, 1 microliter of tear fluid will be collected in both eyes of each subject.

Intervention type: DIAGNOSTIC_TEST
Intervention: Tear fluid sampling
Description: Using microcapillary tubes, 1 microliter of tear fluid will be collected in both eyes of each subject.

Intervention type: DIAGNOSTIC_TEST
Intervention: Impression Cytology
Description: Under topical anesthesia, impression cytology sampling will be performed in the temporal bulbar conjunctiva of both eyes of each subject.

Intervention type: DIAGNOSTIC_TEST
Intervention: Impression Cytology
Description: Under topical anesthesia, impression cytology sampling will be performed in the temporal bulbar conjunctiva of both eyes of each subject.

Intervention type: DIAGNOSTIC_TEST
Intervention: Impression Cytology
Description: Under topical anesthesia, impression cytology sampling will be performed in the temporal bulbar conjunctiva of both eyes of each subject.
Study: NCT06113731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA Vaccine (ZSVG-02-O)
Description: 30 μg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA Vaccine (ZSVG-02-O)
Description: 30 μg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA Vaccine (ZSVG-02-O)
Description: 60 μg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA Vaccine (ZSVG-02-O)
Description: 60 μg

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine (Vero Cell) ,Inactivated
Description: COVILO

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine (Vero Cell) ,Inactivated
Description: COVILO
Study: NCT05451693

Intervention type: BEHAVIORAL
Intervention: Outreach-ER
Description: The intervention is similar to other care intervention/support programs such as REACH or New York University Caregiver Intervention (NYCUI). The Intervention is designed to be delivered over phone/virtual and in-home and will be conducted by Amplio, LLC consultants.
Study: NCT04696601

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Olfactory test
Description: The olfactory test (Olfascan) is in the form of a paper stick, previously impregnated with an odorant (non-liquid). It is placed a few centimetres from the participant's nose at the time of the test. It is a single-use test, without contact with the participant.
Study: NCT04902937

Intervention type: RADIATION
Intervention: Adjuvant radiotherapy
Description: Guideline-based therapy of primary non-metastatic early breast carcinoma

Intervention type: RADIATION
Intervention: Adjuvant radiotherapy
Description: Guideline-based therapy of primary non-metastatic early breast carcinoma

Intervention type: DRUG
Intervention: neoadjuvant and adjuvant chemotherapy
Description: Guideline-based therapy of primary non-metastatic early breast carcinoma

Intervention type: DRUG
Intervention: neoadjuvant and adjuvant chemotherapy
Description: Guideline-based therapy of primary non-metastatic early breast carcinoma
Study: NCT05129566

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IOL Clareon AutonoMe
Description: Phacoemulsification of cataract with implantation of two types of IOLs - Clareon AutonoMe and Hoya iSert 251. Operations will be performed by one surgeon using the Centurion vision system under control of the Verion navigation system. The Verion system will be used for capsulorhexis and IOL centration (limbus centration).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IOL Hoya iSert 251
Description: Phacoemulsification of cataract with implantation of two types of IOLs - Clareon AutonoMe and Hoya iSert 251. Operations will be performed by one surgeon using the Centurion vision system under control of the Verion navigation system. The Verion system will be used for capsulorhexis and IOL centration (limbus centration).
Study: NCT04895384

Intervention type: DEVICE
Intervention: Edwards ClearSight and Masimo SET
Description: Placement of Edwards ClearSight and Masimo SET on the patient intraoperatively.
Study: NCT05148481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB104
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB104
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study: NCT05091125

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic performance of the S100B protein dosage
Description: Dosage of the S100B protein in patients with mild head trauma with complication risks
Study: NCT05320003

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Inky foot analysis
Description: Inky foot analysis to confirm the diagnosis of pes planus

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Evaluation of plantar pressure with pedobarography
Description: Evaluation of plantar pressure distribution by pedobarography in individuals with pes planus

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Balance assessment with computerized posturography
Description: Evaluation of fall risk with computerized posturography
Study: NCT04836884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Vascular Anomaly/Malformation Biopsy
Description: US-guided percutaneous vascular anomaly core needle biopsy of up to 10 cores using an 18-gauge co-axial core needle biopsy device at the time of clinically indicated sclerotherapy, embolization or ablation treatment.
Study: NCT05688332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voglibose + Metformin
Description: In treatment group B, 59 participants will also be randomly assigned to the voglibose 0.2/0.3mg TDS + metformin 500mg BD treatment combination to be taken orally daily, during or immediately after meals with dose titration at day 6 and 12 if the average fasting blood glucose (FBG) level is ≥7 mmol/L (126 mg/dL) and then dosage will be maintained for the remainder of the treatment period Participants in the intervention group initially receiving voglibose 0.2mg + metformin 500mg BD will be dose-titrated to voglibose 0.3mg +metformin 1g BD.~The duration of therapy for each participant will be 12 weeks, which is the minimum period for evaluating the primary endpoint.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glibenclamide + Metformin
Description: The drugs (glibenclamide + metformin), in the control or comparator group will also be taken orally, glibenclamide once a day (OD) before meals, and metformin twice a day (BD) also before meals. These drugs will also be taken with a dose-titration at days 6 and 12 if the average is FBG level will be ≥ 7 mmol/L and the dose will be maintained for the remainder of the study period.~The duration of therapy for each participant will be 12 weeks, which is the minimum period for evaluating the primary endpoint. In this group, participants will initially receive glibenclamide 5mg once daily (OD) + metformin 500mg BD then will be dose-titrated to glibenclamide 10mg OD + metformin 1g BD.
Study: NCT05636267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK119
Description: AK119 IV every 3 weeks.
Study: NCT05015270

Intervention type: DIAGNOSTIC_TEST
Intervention: Medications or percutaneous coronary intervention
Description: In this study, we will for the first analyze the correlation of proteins concentration with coronary artery disease burden. Next, the prediction of proteins for one-year clinical events will be further analyzed

Intervention type: DIAGNOSTIC_TEST
Intervention: Medications or percutaneous coronary intervention
Description: In this study, we will for the first analyze the correlation of proteins concentration with coronary artery disease burden. Next, the prediction of proteins for one-year clinical events will be further analyzed
Study: NCT05917054

Intervention type: OTHER
Intervention: use of bipolar vascular sealing method on the renal allograft at the back-table stage
Description: Ligation of small vessels and lymphatics of the renal graft at the back-table stage prior to transplantation to the recipient is a routine practice in kidney transplantation. Bipolar vascular sealing method will be used for this purpose in Group 1, while the conventional silk-tie method will be used in Group 2.

Intervention type: OTHER
Intervention: use of bipolar vascular sealing method on the renal allograft at the back-table stage
Description: Ligation of small vessels and lymphatics of the renal graft at the back-table stage prior to transplantation to the recipient is a routine practice in kidney transplantation. Bipolar vascular sealing method will be used for this purpose in Group 1, while the conventional silk-tie method will be used in Group 2.
Study: NCT05310331

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Donafenib combined with paclitaxel and platinum ± PD-1 antibody
Description: Patients will receive Donafenib (200mg, bid) combined with paclitaxel (135mg/m2) and cisplatin (creatinine clearance rate \> 60ml/min, 50 mg/m2) or paclitaxel (175 mg/m2) and carboplatin AUC=5 (40ml/min \< creatinine clearance rate \< 60ml/min) ± PD-1 antibody every 3 weeks.
Study: NCT04523961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.5 g of lidocaine 23% / tetracaine 7% ointment without occlusion
Description: Topical anesthetic used to numb the skin prior to laser procedures

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 7.5 g lidocaine 2.5%/ prilocaine 2.5% cream with occlusion
Description: Topical anesthetic used to numb the skin prior to laser procedures
Study: NCT06407531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR-G
Description: Patients watched videos with virtual glasses before undergoing colonoscopy
Study: NCT05633173

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided erector spinae plan block
Description: Ultrasound-guided erector spina plan block was performed for patients in group E for postoperative analgesia. The patients were placed in the lateral decubitus position and the linear ultrasound probe was placed longitudinally into the sterilized area 1-2 cm lateral to the spinous process of the L1 vertebra. After visualizing the erector spina muscle and the transverse process, the transverse process was reached by pushing forward the 22 gauge, 50 mm needle in the direction from cranial to caudal. Hydrodissection was performed with 1 ml of saline for confirmation. 0.5 mL kg-1 dose of 0.25% bupivacaine was injected under the erector spina muscle at the level of the 1st lumbar vertebra by aspiration every 2 mL.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided caudal block
Description: The patients in group C underwent ultrasound guided caudal block for postoperative analgesia. By placing the patients in the lateral decubitus position, the linear ultrasound probe was placed longitudinally on the sterilized area on the midline of the sacrum, and access was provided with a 2.5 cm 22 gauge needle on the dorsal skin of the sacral hiatus at a 90° position. The sacrococcygeal ligament was crossed, the needle was oriented approximately 25° and advanced approximately 2 to 3 mm to reach the sacral canal. When it was understood that the sacral hiatus had been entered, 0.5 mL kg-1 0.25% bupivacaine was injected by aspirating every 2 mL after the location was confirmed with the negative aspiration method.
Study: NCT06431269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening for neurodevelopmental disorders by an advanced practice nurse
Description: Screening for neurodevelopmental disorders by an advanced practice nurse with Ages \& Stages Questionnaires (ASQ-3) and Haute Autorité de Santé (HAS) identification scale
Study: NCT06245382

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Goode Health Beverage
Description: This is a commercially available beverage powder that is high is healthy ingredients that are believed to be beneficial for physiological health.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vanilla Base Beverage Blend
Description: This is a commercially available beverage powder.
Study: NCT05056506

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EPLBD
Description: Endoscopic papillary large balloon dilation for Choledocholithiasis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ELPBD+ESD
Description: Endoscopic papillary balloon dilation combined with limited endoscopic sphincterotomy for Choledocholithiasis
Study: NCT06402032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hesperidin
Description: Hesperidin is a natural flavonoid with well-known of its anti-inflammatory properties in many disease. Hesperidin in previous studies has been documented to reduce inflammation as well as pain through suppression of cytokine production, NF-κB activity, and oxidative stress. Hesperidin, as a natural product, have been considered as a promising pulp capping material in several invitro and animal studies. However, the regenerative effect of hesperidin as pulp capping material in human teeth has not yet been reported.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mineral Trioxide Aggregate (MTA)
Description: Mineral trioxide aggregate is a cementitious material having various advantages as it is biocompatible, bioactive, osteo-inductive, non-resorbable material with exciting clinical applications, stimulating reparative continuous dentin formation along with maintaining the integrity of the pulp. Moreover, mineral trioxide aggregate provides seal to tooth structure and is of high strength. It is considered the gold standard material for direct pulp capping.
Study: NCT05080452

Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic infrared thermography (DIRT)
Description: Visualizing hot spots

Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic infrared thermography (DIRT)
Description: Visualizing hot spots
Study: NCT05915767

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive leaf tea
Description: Fresh olive leaves will be procured from Chakwal, Pakistan. The leaves will be rinsed to remove dust and debris and dried at 40℃ in the oven. The leaves will be ground into powder form and then incorporated in tea bags containing 1.8 g leave powder/tea bag. Participants in treatment group will be instructed to dip the tea bag in 200-250 ml boiling water for 3-5 minutes.
Study: NCT04205760

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nutrition + exercise
Description: Patients will receive preoperative optimization consisting of oral nutrition support (Fresubin 3.2 kcal) and bed-cycling (50 minutes per day) for 5-14 days before surgery.
Study: NCT05487807

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Will be receiving nicotine therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Will be receiving nicotine therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: text messaging
Description: Will be enrolled in an texting app

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: text messaging
Description: Will be enrolled in an texting app
Study: NCT05636267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: AK112 IV every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: AK112 IV every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: AK112 IV every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed IV every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin IV every 3 weeks.
Study: NCT05498207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maya App
Description: Participants will utilize the Maya App for at least 20 minutes per day, 2 days per week, for 6 weeks. Additionally, participants will complete assessments at baseline, 3 months, 6 months, 9 months and 12 months (this includes specimen collections, interviews, and surveys). Participants will also be asked to wear a Fitbit for 12 months.
Study: NCT04850066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Equine-assisted intervention
Description: Usual care including an equine-assisted intervention carried out on foot, next to the horse, in 3 sessions of 3 hours each, spread over 4 weeks. This program is based on self-awareness, communication, assertiveness and adaptability.
Study: NCT02827747

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidants (Vitamins A,C,E) plus GSH
Description: Study medication would contain 500 milligrams of vitamin C, 400 International Units of vitamin E, and 15 milligrams of beta-carotene (the equivalent to 25,000 International Units of vitamin A).The study medication would also contain 1000mg of Glutathione (GSH).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidants (Vitamins A,C,E) plus GSH
Description: Study medication would contain 500 milligrams of vitamin C, 400 International Units of vitamin E, and 15 milligrams of beta-carotene (the equivalent to 25,000 International Units of vitamin A).The study medication would also contain 1000mg of Glutathione (GSH).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo pill

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Centrum
Description: Centrum
Study: NCT06306261

Intervention type: OTHER
Intervention: questionnaire
Description: UC patients will be subjected to a questionnaire each month about their habits.
Study: NCT02827747

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Centrum
Description: Centrum

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Sources
Description: From dietary sources of vitamins.
Study: NCT06128408

Intervention type: DRUG
Intervention: risperidone, olanzapine, aripiprazole
Description: Participants from the retrospective cohort were randomly assigned to one of the three drug groups of risperidone, olanzapine and aripiprazole for a period of 1 years of treatment.
Study: NCT04801511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: High-dose Intravenous Vitamin C will be delivered on the day of radiotherapy, in order to reduce the acute toxicity of chemoradiotherapy.
Study: NCT05797636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: The study intervention is modulation of cortical excitation to inhibition (E/I) balance in the dorsolateral prefrontal cortex (dlPFC) by means of 2 trains of spaced continuous theta burst stimulation (cTBS) using a transcranial magnetic stimulation device. As prior work (Huang et al 2005; Chung et al. 2018) has shown that cTBS reliably decreases the cortical E/I ratio with diverse cortical targets, the Investigators expect to replicate a reduction in E/I balance when applied. The mechanism of action is thought to be an increase in inhibitory neurotransmission across diverse timescales. The endpoint of this stimulation will be a decrease in the local E/I ratio that should last at least 60 minutes post-stimulation (Chung et al., 2018).~In separate sessions, all participants will receive stimulation to either the dorsolateral prefrontal cortex (dlPFC) or to the angular gyrus (AG). The Investigators will contrast the effects of dlPFC cTBS with control cTBS to the AG.
Study: NCT04999345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Progressive resistance exercise and graded aerobic exercise will be provided for those in the experimental group.